Photovoice: A Novel Approach to Improving Antituberculosis Treatment Adherence in Pune, India
Table 1
Demographic, risk, and treatment outcomes of TB patients who viewed the Photovoice video and comparison group who did not, Pune, India.
Characteristics
Photovoice
Comparison
Total
value
(%)
(%)
Gender
Male
87
(64.4)
77
(54.6)
164
0.096
Female
48
(35.6)
64
(45.4)
112
Age categories (years)
<15
17
(12.6)
18
(12.8)
35
0.148
15–25
23
(17.0)
30
(21.3)
53
26–35
33
(24.4)
42
(29.8)
75
36–45
31
(23.0)
33
(23.4)
64
46–55
23
(17.0)
9
(6.4)
32
>55
8
(5.9)
9
(6.4)
17
HIV status
Positive
45
(33.3)
41
(29.1)
86
0.743
Negative
66
(48.9)
74
(52.5)
140
Unknown
24
(17.8)
26
(18.4)
50
Type of tuberculosis
Sputum positive pulmonary
56
(41.5)
52
(36.9)
108
0.423
Sputum negative pulmonary
31
(22.9)
28
(19.9)
59
Extrapulmonary
48
(35.6)
61
(43.3)
109
Total number of missed doses
No missed doses
102
(75.6)
66
(46.8)
168
0.000
1 or more missed doses
33
(24.4)
75
(53.2)
108
Sputum at the start of initiation phase1
Negative
81
(60.0)
95
(67.4)
176
0.125
Positive
54
(40.0)
46
(32.6)
100
Sputum at the end of initiation phase1
Negative
133
(98.5)
124
(87.9)
257
0.000
Positive
2
(1.5)
17
(12.1)
19
Treatment outcomes
Successful
125
(92.6)
115
(81.6)
240
0.000
Unsuccessful2
10
(7.4)
26
(18.4)
36
Antituberculosis treatment (ATT) is comprised of 2 phases: intensive phase (IP) (24 doses of isoniazid, rifampicin, pyrazinamide, and ethambutol by directly observed therapy (DOT) thrice a week on alternate days for 8 weeks) and continuation phase (CP) (54 doses of isoniazid and rifampicin given thrice a week on alternate days with at least first dose of every week being directly observed). 2Patients with treatment failure and patients who transferred, lost to follow-up, or died.
